Swedencare Past Earnings Performance
Past criteria checks 2/6
Swedencare has been growing earnings at an average annual rate of 25%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 56.1% per year. Swedencare's return on equity is 0.9%, and it has net margins of 3%.
Key information
25.0%
Earnings growth rate
8.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 56.1% |
| Return on equity | 0.9% |
| Net Margin | 3.0% |
| Next Earnings Update | 25 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Swedencare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,414 | 72 | 830 | 0 |
| 31 Dec 23 | 2,338 | 59 | 803 | 0 |
| 30 Sep 23 | 2,199 | 87 | 736 | 0 |
| 30 Jun 23 | 2,076 | 53 | 712 | 0 |
| 31 Mar 23 | 1,987 | 97 | 690 | 0 |
| 31 Dec 22 | 1,843 | 95 | 640 | 0 |
| 30 Sep 22 | 1,600 | 98 | 547 | 0 |
| 30 Jun 22 | 1,335 | 105 | 456 | 0 |
| 31 Mar 22 | 1,019 | 60 | 345 | 0 |
| 31 Dec 21 | 773 | 55 | 259 | 0 |
| 30 Sep 21 | 618 | 40 | 205 | 0 |
| 30 Jun 21 | 465 | 44 | 146 | 0 |
| 31 Mar 21 | 337 | 34 | 114 | 0 |
| 31 Dec 20 | 240 | 33 | 87 | 0 |
| 30 Sep 20 | 174 | 34 | 72 | 0 |
| 30 Jun 20 | 136 | 28 | 61 | 0 |
| 31 Mar 20 | 134 | 30 | 58 | 0 |
| 31 Dec 19 | 127 | 30 | 54 | 0 |
| 30 Sep 19 | 121 | 30 | 50 | 0 |
| 30 Jun 19 | 113 | 28 | 48 | 0 |
| 31 Mar 19 | 108 | 27 | 47 | 0 |
| 31 Dec 18 | 99 | 23 | 44 | 0 |
| 30 Sep 18 | 94 | 23 | 41 | 0 |
| 30 Jun 18 | 92 | 20 | 42 | 0 |
| 31 Mar 18 | 85 | 17 | 41 | 0 |
| 31 Dec 17 | 86 | 17 | 40 | 0 |
| 30 Sep 17 | 78 | 12 | 39 | 0 |
| 30 Jun 17 | 70 | 11 | 35 | 0 |
| 31 Mar 17 | 63 | 12 | 31 | 0 |
| 31 Dec 16 | 54 | 10 | 28 | 0 |
| 30 Sep 16 | 43 | 9 | 23 | 0 |
| 30 Jun 16 | 37 | 8 | 19 | 0 |
| 31 Mar 16 | 34 | 8 | 15 | 0 |
| 31 Dec 15 | 27 | 7 | 10 | 0 |
| 31 Dec 14 | 24 | 4 | 9 | 0 |
| 31 Dec 13 | 18 | 0 | 9 | 0 |
Quality Earnings: 7XY has high quality earnings.
Growing Profit Margin: 7XY's current net profit margins (3%) are lower than last year (4.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7XY's earnings have grown significantly by 25% per year over the past 5 years.
Accelerating Growth: 7XY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 7XY had negative earnings growth (-26.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.2%).
Return on Equity
High ROE: 7XY's Return on Equity (0.9%) is considered low.